• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002437.SZ
Share

HARBIN GLORIA PHARMACEUTICALS Co., LTD Stocks

CN¥ 3.02Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.03B

CN¥ 3.02
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Harbin Gloria Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical enterprise primarily focused on the research, development, manufacturing, and commercialization of various medicinal products within the People's Republic of China. The company's comprehensive portfolio addresses a broad spectrum of therapeutic areas, including cardiac and cerebrovascular health, skeletal muscle system support, and urinary tract conditions. It also provides vitamins and minerals, as well as medications for oncology, endocrine disorders, anti-infective treatments, respiratory ailments, antihistamine purposes, and peptic concerns, among other pharmaceutical goods. Established in 2000, the firm's headquarters are located in Harbin, also situated in the People's Republic of China.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 002437.SZ is 3.23 and suggests 3.19% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 19:14

"Life is unpredictable": Buffett has set a deadline for distributing his shares

14.07.2026 18:30

Revolut Will Participate in Testing the Digital Euro

14.07.2026 18:12

Oil at $87, Houthi attacks, strikes on UAE tankers: What’s happening in the Middle East?

14.07.2026 17:48

Consumer inflation in the U.S. turned out to be much lower than expected

14.07.2026 17:40

Nebius closed a $1 billion deal with a startup founded by former Google AI developers

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026